TauRx – a spin out from the University of Aberdeen

TauRx are dedicated to studying neurodegenerative diseases and are at the forefront of Alzheimer’s research.  The company is a spin out of the University of Aberdeen. TauRx’s main product, HMTM, is a drug with the potential to slow disease progression in Alzheimer’s and behavioural variant frontotemporal dementia.  

TauRx is named after the tau protein, whose role in neurodegenerative diseases has become so much clearer over years of research. 

Professor Wischik is board-certified in psychiatry, and professor of Old Age Psychiatry at the University of Aberdeen, Scotland. A pioneer in Tau research, he discovered the tau protein compositional structure of the Alzheimer’s tangles and established that it was possible to dissolve tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors.

TauRx has been going through the various phases of clinical trials. Confirmatory phase III trials in 2022 used the knowledge gained from previous trials to prove the efficacy of the product at low dose and as an isolated treatment. The results showed sustained cognitive improvement over 18 months in patients with Mild Cognitive Impairment due to Alzheimer’s disease,  

In 2024 TauRx submitted its HMTM product to the UK’s Medicines and Healthcare products Regulatory Agency as a tablet to treat mild cognitive impairment and the mild to moderate stages of Alzheimer’s disease.